Bayer Links OTC User Fees To Exclusivity, Hisamitsu Pans General Concept
This article was originally published in The Pink Sheet
Executive Summary
Bayer HealthCare encourages FDA to grant periods of market exclusivity to firms charged user fees for monograph proposal, while Hisamitsu America questions FDA's basic rationale for why a fee is needed to improve the monograph system.
You may also be interested in...
OTC Industry News Roundup: Earnings, User Fee Webinar, UK Ad Enforce
Sensodyne shines for Glaxo-Novartis JV; and international growth leads Prestige Brands OTCs.
CDER Asked To Shed More Light On Potential Monograph User Fees
While Director Janet Woodcock and other CDER officials explain the center's reasons for proposing a monograph program user fee, some stakeholders suggest the agency explain more about how the program would work.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”